Treatments for AD: towards the right target at the right time

Nature Reviews Neurology, Published online: 01 September 2023; doi:10.1038/s41582-023-00869-0Results from the phase III trials of the amyloid-targeting antibodies donanemab and solanezumab add further evidence that amyloid pathology is a key driver of cognitive decline in Alzheimer disease. The mixed results highlight important considerations for future trials and clinical practice.
Source: Nature Reviews Neurology - Category: Neurology Authors: Source Type: research